CompletedNot Applicable

Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes

South Korea1,538 participantsStarted 2022-10-19

Plain-language summary

A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® according to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women aged ≥19 years * Diagnosed with hypercholesterolemia * LDL-C level meets cardiovascular/cerebrovascular risk group classification * Willing to participate for 12 months * Provided written informed consent Exclusion Criteria: \- Contraindications to Livalozet®

What they're measuring

Percent change from baseline in LDL-C level at Week 24

Timeframe: From enrollment to the end of treatment at 24 weeks

Trial details

NCT IDNCT07382778

SponsorJW Pharmaceutical

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-06-13

View on ClinicalTrials.gov More Hypercholesterolemia trials